Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Osimertinib and Navitoclax in Treating Patients With EGFR-Positive Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02520778
Recruitment Status : Recruiting
First Posted : August 13, 2015
Last Update Posted : April 23, 2019
Sponsor:
Information provided by (Responsible Party):
National Cancer Institute (NCI)

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Recruiting
  Estimated Primary Completion Date : July 30, 2019
  Study Completion Date : No date given